Market Place
Sourcing Support
Minerva`s schizophrenia drug rejected by FDA for 2nd time
28 Feb 2024 //
FIERCE BIOTECH
Minerva Neurosciences Announces Update on its NDAfor Roluperidone
10 May 2023 //
GLOBENEWSWIRE
Minerva Neurosciences Announces the NDA Filing for Roluperidone
01 May 2023 //
GLOBENEWSWIRE
Minerva Receives Refusal to File Letter from FDA for its NDA for Roluperidone
17 Oct 2022 //
GLOBENEWSWIRE
Minerva Submits New Drug Application to FDA for Roluperidone
22 Aug 2022 //
GLOBENEWSWIRE
FDA Recommends Type C Meeting for Minerva to Discuss Evidence for Roluperidone
03 Nov 2021 //
GLOBENEWSWIRE
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and year Results
08 Mar 2021 //
GLOBENEWSWIRE
The FDA spells out 4 reasons why it hates Minerva’s NDA ideas
02 Dec 2020 //
ENDPTS
Minerva Neurosciences’ roluperidone fails in Phase III study
01 Jun 2020 //
CLINICALTRIALSARENA
Minerva`s Announces Completion of Patient Enrollment Ph3 Trial of Roluperidone
05 Feb 2020 //
EINPRESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.